Cisatracurium Besylate Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., A Pfizer Company

The FDA lists a drug shortage record for Cisatracurium Besylate Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on May 6, 2026.

Shortage details

Status
To Be Discontinued
Company
Hospira, Inc., A Pfizer Company
Package NDC
0409-1103-01
Dosage Form
Injection
Presentation
Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)
Initial Posting
May 6, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.